Dr Baker has a background in immunology with >15 years experience in developing biologics (for biotech and pharma companies), and has a successful track record of implementing M&A's and IPO exit strategies.
Dr Baker currently holds positions as CSO at Denceptor (Cambridge, UK) and VP Immunology & Oncology at Celentyx (Birmingham, UK).
Previous positions include CSO at Abzena, CEO/CSO (and co-founder) of Antitope, and VP Biologics Discovery at Biovation (subsidiary of Merck KGaA). Pre-industry experience includes postdoctoral positions in Cambridge and a PhD in cellular immunology from University of Birmingham UK.